Arrowhead Pharmaceuticals Corp (ARWR) Q4 Revs Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Arrowhead Pharmaceuticals Corp (ARWR) May Be Worth $75-$90 in a Sale - Cantor Fitzgerald
November 26, 2019 1:44 PM ESTCantor Fitzgerald analyst Alethia Young said Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) may be worth $75-$90 in a sale. The analyst reiterated a Neutral rating and $50 price target.
... More